keyword
MENU ▼
Read by QxMD icon Read
search

Mantle cell

keyword
https://www.readbyqxmd.com/read/29234922/pharmacokinetically-targeted-dosed-everolimus-maintenance-therapy-in-lymphoma-patients
#1
L K Schoch, A Asiama, M Zahurak, S Shanbhag, J Hurtt, K Sawyer, L J Swinnen, N Wagner-Johnston, R J Jones, R F Ambinder, Douglas E Gladstone
BACKGROUND: Everolimus, an mTOR inhibitor, is active in refractory lymphomas. However, toxicity with flat dosing limits its usage. Speculatively, pharmacokinetically-targeted dosing could improve tolerability. Therefore, we studied serum-trough dosing with rituximab as maintenance after high-dose cyclophosphamide (HDC) consolidation in lymphoma patients. PATIENTS/METHODS: After HDC, everolimus was dosed to serum trough levels (goal 3-15 ng/mL), with quarterly rituximab infusions for 1 year while maintaining < grade II non-hematologic and < grade III hematologic toxicities...
December 13, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29234188/cranial-nerve-lymphomatosis-magnetic-resonance-imaging-findings-in-a-case-of-mantle-cell-lymphoma
#2
Güliz Yılmaz, Süha Akpınar, Nail Bulakbaşı
No abstract text is available yet for this article.
September 2017: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/29224277/-clinicopathologic-analysis-of-micronodular-thymoma-with-lymphoid-stroma
#3
X Y Wang, M Xu, L G Shi, Y Z Ding, Q Cheng, Y W Zhao
Objective: To investigate the clinicopathologic features of micronodular thymoma with lymphoid stroma(MNT). Methods: Five cases of MNT diagnosed from January 2007 to December 2016 in Henan Provincial People's Hospital were collected.Hematoxylin-Eosin staining and immunohistochemistry were used to evaluate the histological and immunophenotypic characteristics in 5 MNT cases. Epstein-Barr virus (EBV) status was detected by in situ hybridization for EBV-encoded small RNA (EBER). Polymerase chain reaction was used to detect the rearrangement of immunoglobulin genes...
December 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29222478/viscosity-jump-in-the-lower-mantle-inferred-from-melting-curves-of-ferropericlase
#4
Jie Deng, Kanani K M Lee
Convection provides the mechanism behind plate tectonics, which allows oceanic lithosphere to be subducted into the mantle as "slabs" and new rock to be generated by volcanism. Stagnation of subducting slabs and deflection of rising plumes in Earth's shallow lower mantle have been suggested to result from a viscosity increase at those depths. However, the mechanism for this increase remains elusive. Here, we examine the melting behavior in the MgO-FeO binary system at high pressures using the laser-heated diamond-anvil cell and show that the liquidus and solidus of (Mg x Fe1-x )O ferropericlase (x = ~0...
December 8, 2017: Nature Communications
https://www.readbyqxmd.com/read/29222271/optimizing-therapy-for-mantle-cell-lymphoma
#5
REVIEW
Peter Martin
Most people with mantle cell lymphoma (MCL) present with diffuse adenopathy and benefit from early initiation of rituximab and high-dose cytarabine- or bendamustine-based therapies. Some patients, however, present with primarily nonnodal disease that can follow either an indolent or a rapidly progressive, treatment-resistant clinical course. Rarely, patients present with explosive disease that can be challenging to manage and often involves the central nervous system. New agents with improved therapeutic indices facilitate treatment while maintaining quality of life, but also present new complications at the time of treatment failure...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29220870/quantitative-assessment-of-informative-immunophenotypic-markers-increases-the-diagnostic-value-of-immunophenotyping-in-mature-cd5-positive-b-cell-neoplasms
#6
Starostka David, Kriegova Eva, Kudelka Milos, Mikula Peter, Zehnalova Sarka, Radvansky Martin, Papajik Tomas, Kolacek David, Chasakova Katerina, Talianova Hana
BACKGROUND: The data on the clinical utility of the quantitative assessment of immunophenotypes in distinguishing mature CD5-positive B-cell neoplasms is limited. The study aim was to assess the diagnostic value of the quantitative assessment of a panel of 18 markers and to identify the most informative ones. METHODS: The immunophenotype of the neoplastic population was determined in diagnostic specimens from 188 patients. BD FACSCanto II flow cytometer and FACSDiva software were used to analyse the positivity/negativity and mean fluorescence intensity (MFI) of the surface expression of 18 markers...
December 8, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/29218052/spoiling-for-a-fight-b-lymphocytes-as-initiator-and-effector-populations-within-tertiary-lymphoid-organs-in-autoimmunity-and-transplantation
#7
REVIEW
Jawaher Alsughayyir, Gavin J Pettigrew, Reza Motallebzadeh
Tertiary lymphoid organs (TLOs) develop at ectopic sites within chronically inflamed tissues, such as in autoimmunity and rejecting organ allografts. TLOs differ structurally from canonical secondary lymphoid organs (SLOs), in that they lack a mantle zone and are not encapsulated, suggesting that they may provide unique immune function. A notable feature of TLOs is the frequent presence of structures typical of germinal centers (GCs). However, little is known about the role of such GCs, and in particular, it is not clear if the B cell response within is autonomous, or whether it synergizes with concurrent responses in SLOs...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29209955/acalabrutinib-first-global-approval
#8
Anthony Markham, Sohita Dhillon
Acerta Pharma is developing the Bruton's tyrosine kinase inhibitor acalabrutinib (Calquence®) for the treatment of various haematological and solid malignancies. The drug has received accelerated approval from the US FDA for the treatment of mantle cell lymphoma based on the results of a phase II study, and phase III trials in mantle cell lymphoma and chronic lymphocytic leukaemia are currently underway. This article summarizes the milestones in the development of acalabrutinib leading to this first approval for mantle cell lymphoma...
December 5, 2017: Drugs
https://www.readbyqxmd.com/read/29208403/efficacy-of-standard-dose-r-chop-alternating-with-r-hdac-followed-by-autologous-hematopoietic-cell-transplantation-as-initial-therapy-of-mantle-cell-lymphoma-a%C3%A2-single-institution-experience
#9
Yazeed Sawalha, Brian T Hill, Lisa A Rybicki, Danyu Sun, Robert M Dean, Deepa Jagadeesh, Betty K Hamilton, Aaron T Gerds, Ronald M Sobecks, Steven Andresen, Hien K Liu, Navneet S Majhail, Brad Pohlman, Matt E Kalaycio, Brian J Bolwell, Mitchell R Smith
BACKGROUND: Young fit patients with mantle cell lymphoma (MCL) are commonly treated with induction chemotherapy followed by high-dose chemotherapy and autologous hematopoietic cell transplantation (AHCT). Induction regimens with modifications of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and/or incorporation of high-dose cytarabine (HDAC) appear more effective than R-CHOP alone. PATIENTS AND METHODS: We adopted a modification of the Nordic protocol using standard, rather than higher dose R-CHOP, alternating with HDAC (rituximab plus HDAC), for 3 cycles each or, for patients already treated with R-CHOP alone before referral for AHCT, an additional 2 cycles of rituximab plus HDAC...
December 2, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29205868/ficoll-hypaque-separation-vs-whole-blood-lysis-comparison-of-efficiency-and-impact-on-minimal-residual-disease-analysis
#10
E Genuardi, D Barbero, I Dogliotti, B Mantoan, D Drandi, M Gambella, G M Zaccaria, L Monitillo, I Della Starza, M Cavalli, L A De Novi, E Ciabatti, S Grassi, A Gazzola, C Mannu, I Del Giudice, S Galimberti, C Agostinelli, P P Piccaluga, M Ladetto, S Ferrero
INTRODUCTION: The high-throughput era remarkably changed molecular laboratory practice. Actually, the increasing number of processed samples requires to reduce the risk of operator biases, by automating or simplifying as much as possible both the analytical and the pre-analytical phases. Minimal residual disease (MRD) studies in hematology often require a simultaneous processing of many bone marrow and peripheral blood samples from patients enrolled in prospective, multicenter, clinical trials, monitored at several planned time points...
December 4, 2017: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/29203224/gastrointestinal-mantle-cell-lymphoma-presenting-as-lymphomatous-polyposis
#11
Galen Leung, Jela Bandovic, Jonathan M Buscaglia
No abstract text is available yet for this article.
December 1, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29202016/inhibition-of-ngly1-inactivates-the-transcription-factor-nrf1-and-potentiates-proteasome-inhibitor-cytotoxicity
#12
Frederick M Tomlin, Ulla I M Gerling-Driessen, Yi-Chang Liu, Ryan A Flynn, Janakiram R Vangala, Christian S Lentz, Sandra Clauder-Muenster, Petra Jakob, William F Mueller, Diana Ordoñez-Rueda, Malte Paulsen, Naoko Matsui, Deirdre Foley, Agnes Rafalko, Tadashi Suzuki, Matthew Bogyo, Lars M Steinmetz, Senthil K Radhakrishnan, Carolyn R Bertozzi
Proteasome inhibitors are used to treat blood cancers such as multiple myeloma (MM) and mantle cell lymphoma. The efficacy of these drugs is frequently undermined by acquired resistance. One mechanism of proteasome inhibitor resistance may involve the transcription factor Nuclear Factor, Erythroid 2 Like 1 (NFE2L1, also referred to as Nrf1), which responds to proteasome insufficiency or pharmacological inhibition by upregulating proteasome subunit gene expression. This "bounce-back" response is achieved through a unique mechanism...
November 22, 2017: ACS Central Science
https://www.readbyqxmd.com/read/29199178/carbonic-anhydrase-2-like-in-the-giant-clam-tridacna-squamosa-characterization-localization-response-to-light-and-possible-role-in-the-transport-of-inorganic-carbon-from-the-host-to-its-symbionts
#13
Yuen K Ip, Clarissa Z Y Koh, Kum C Hiong, Celine Y L Choo, Mel V Boo, Wai P Wong, Mei L Neo, Shit F Chew
The fluted giant clam, Tridacna squamosa, lives in symbiosis with zooxanthellae which reside extracellularly inside a tubular system. Zooxanthellae fix inorganic carbon (Ci) during insolation and donate photosynthate to the host. Carbonic anhydrases catalyze the interconversion of CO2 and HCO3-, of which carbonic anhydrase 2 (CA2) is the most ubiquitous and involved in many biological processes. This study aimed to clone a CA2 homolog (CA2-like) from the fleshy and colorful outer mantle as well as the thin and whitish inner mantle of T...
December 2017: Physiological Reports
https://www.readbyqxmd.com/read/29196411/expression-of-tp53-is-associated-with-outcome-of-mcl-independent-of-mipi-and-ki-67-in-trials-of-the-european-mcl-network
#14
Sietse M Aukema, Eva Hoster, Andreas Rosenwald, Danielle Canoni, Marie-Hélène Delfau-Larue, Grzegorz Rymkiewicz, Christoph Thorns, Sylvia Hartmann, Hanneke Kluin-Nelemans, Olivier Hermine, Martin Dreyling, Wolfram Klapper
Currently, prediction of time to treatment failure and overall survival in mantle cell lymphoma is based on the clinical factors included in the mantle cell lymphoma international prognostic index (MIPI) and proliferation assessed by Ki67. However, P53 and SOX11 immunohistochemistry might improve risk stratification. We performed SOX11 and P53 immunohistochemistry on the so far largest published cohort of lymphoma specimens (n=365). All patients were treated in prospective trials of the European MCL Network...
December 1, 2017: Blood
https://www.readbyqxmd.com/read/29195616/pet-ct-for-lymphoma-post-therapy-response-assessment-in-other-lymphomas-response-assessment-for-autologous-stem-cell-transplant-and-lymphoma-follow-up
#15
REVIEW
Shawn Karls, Hina Shah, Heather Jacene
FDG-PET/CT is an established first-line diagnostic imaging tool used in the staging of most lymphomas and for post-therapy response assessment in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL). Many of the subtypes of lymphoid neoplasms classified by the World Health Organization demonstrate significant FDG-avidity or uptake; however, many guidelines and Lugano classification do not recommend the use of FDG-PET/CT in assessing response to therapy for these non-HL, non-DLBCL subtypes as a first-line diagnostic tool...
January 2018: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/29194473/esmo-consensus-conference-on-malignant-lymphoma-general-perspectives-and-recommendations-for-the-clinical-management-of-the-elderly-patient-with-malignant-lymphoma
#16
C Buske, M Hutchings, M Ladetto, V Goede, U Mey, P Soubeyran, M Spina, R Stauder, M Trnený, U Wedding, P Fields
The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use, and (3) the 'ultra-high-risk' group...
November 29, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29193019/prospective-subgroup-analyses-of-the-randomized-mcl-002-sprint-study-lenalidomide-versus-investigator-s-choice-in-relapsed-or-refractory-mantle-cell-lymphoma
#17
Luca Arcaini, Thierry Lamy, Jan Walewski, David Belada, Jiri Mayer, John Radford, Wojciech Jurczak, Franck Morschhauser, Julia Alexeeva, Simon Rule, José Cabeçadas, Elias Campo, Stefano A Pileri, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Marek Trnĕný
In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1-21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine)...
November 28, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/29191715/vcr-cvad-induction-chemotherapy-followed-by-maintenance-rituximab-produces-durable-remissions-in-mantle-cell-lymphoma-a-wisconsin-oncology-network-study
#18
Julie E Chang, Lakeesha L Carmichael, KyungMann Kim, Christopher Peterson, David T Yang, Anne M Traynor, Jae E Werndli, Michael S Huie, Thomas A McFarland, Michael Volk, Jules Blank, Natalie S Callander, Walter L Longo, Brad S Kahl
INTRODUCTION: VcR-CVAD was developed as an intermediate-intensity induction regimen with maintenance rituximab (MR) to improve remission durations after first-line therapy for mantle cell lymphoma (MCL) in older and younger patients with MCL. PATIENTS AND METHODS: Patients with previously untreated MCL received VcR-CVAD induction chemotherapy for 6 cycles (21-day cycles). Patients achieving at least a partial response received rituximab consolidation (375 mg/m2 × 4 weekly doses) and MR (375 mg/m2 every 12 weeks × 20 doses)...
November 4, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29182526/immunohistochemical-analysis-of-rat-renal-tumours-caused-by-ochratoxin-a
#19
Diana Herman, Peter Mantle
Experimental renal cancer caused by ochratoxin A (OTA) in rats was first defined in the US National Toxicology Program (1989) and raised questions about any aetiological role in human urinary tract tumours. A review of histopathology in several rat kidney tumours from dietary OTA in recently described London studies, augmented by clinical immunohistochemistry for the first time for this mycotoxin, establishes their renal tubular cell origin. It had been assumed that the toxin might cause the human urothelial tumours associated with Balkan endemic nephropathy, but the present study could not support this...
November 28, 2017: Toxins
https://www.readbyqxmd.com/read/29173978/-allogeneic-hematopoietic-cell-transplantation-for-hodgkin-s-disease-mantle-cell-lymphoma-and-other-rare-entities-guidelines-from-the-francophone-society-of-bone-marrow-transplantation-and-cellular-therapy-sfgm-tc
#20
Jordan Gauthier, Sylvain Chantepie, Krimo Bouabdallah, Edgar Jost, Stéphanie Nguyen, Anne-Claire Gac, Gandhi Damaj, Rémy Duléry, Mauricette Michallet, Jérémy Delage, Philippe Lewalle, Franck Morschhauser, Gilles Salles, Ibrahim Yakoub-Agha, Jérôme Cornillon
Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic haematopoietic cell transplantation is a potentially curative option, in particular in the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic haematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting...
November 22, 2017: Bulletin du Cancer
keyword
keyword
52380
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"